Aurobindo Pharma submits original application for Eluxadoline (ANDA213511)
Aurobindo Pharma has submitted an original application for Eluxadoline under ANDA213511, which is currently under standard review by the FDA.
Asset / Drug
Drug and asset intelligence for Viberzi with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.